🇺🇸 FDA
Pipeline program

TAK-019

TAK-019-3001

Phase 3 mab completed

Quick answer

TAK-019 for Coronavirus Disease (COVID-19) is a Phase 3 program (mab) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).

Program details

Company
TAKEDA PHARMACEUTICAL CO LTD
Indication
Coronavirus Disease (COVID-19)
Phase
Phase 3
Modality
mab
Status
completed

Clinical trials